Physician profile
Robin Hougen
NPI 1710397872
$2,011.10
in general payments reported to CMS, 2019-2025
26 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $65.90 · 2021: $244 · 2022: $106 · 2023: $411 · 2024: $356 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $310.27 | 2023-2025 | Valtoco |
| Greenwich Biosciences, INC. | $170.40 | 2019-2021 | |
| Biogen, INC. | $169.98 | 2019-2023 | Spinraza |
| Otter Pharmaceuticals, LLC | $166.30 | 2024-2025 | Sympazan |
| Livanova USA, INC. | $149.72 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sunovion Pharmaceuticals INC. | $139.89 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $133.62 | 2021 | |
| Sumitomo Pharma America, INC. | $102.55 | 2023-2024 | Aptiom |
| Acadia Pharmaceuticals INC | $96.01 | 2023-2024 | Daybue |
| Ucb, INC. | $83.61 | 2022-2023 | Briviact |
| Jazz Pharmaceuticals INC. | $62.49 | 2024 | |
| Immedica Pharma US, INC. | $52.26 | 2023-2024 | |
| Biocodex, INC. | $46.12 | 2023 | Diacomit |
| Zogenix INC. | $35.32 | 2021 | |
| Aquestive Therapeutics, INC. | $32.80 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itf Therapeutics LLC | $31.17 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $30.19 | 2024 | |
| Biomarin Pharmaceutical INC. | $29.79 | 2020-2021 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $28.64 | 2019 | |
| Saol Therapeutics INC. | $25.98 | 2019 | |
| Ptc Therapeutics, INC. | $25.67 | 2020 | |
| Sk Life Science, INC. | $23.17 | 2023 | |
| Collegium Pharmaceutical, INC. | $19.81 | 2025 | Jornay Pm |
| Nobelpharma America, LLC | $17.25 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.44 | 2023 | Triptodur |
| Shire North American Group INC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Hougen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.